A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O’Day et al. · Clinical Cancer Research · 2009 · 3.2K citations

Medicine, Immunology, Oncology +17

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16